Trial · NCT01713946
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Everolimus LT Target of 3 to 7 ng/mL | 117 | |
| Overall Study | STARTED | Everolimus HT Target of 9 to 15 ng/mL | 130 | |
| Overall Study | STARTED | Placebo | 119 | |
| Overall Study | Completed Core Phase | Everolimus LT Target of 3 to 7 ng/mL | 110 | |
| Overall Study | Completed Core Phase | Everolimus HT Target of 9 to 15 ng/mL | 122 | |
| Overall Study | Completed Core Phase | Placebo | 114 | |
| Overall Study | Continued in Ext. Phase | Everolimus LT Target of 3 to 7 ng/mL | 110 | |
| Overall Study | Continued in Ext. Phase | Everolimus HT Target of 9 to 15 ng/mL | 119 | |
| Overall Study | Continued in Ext. Phase | Placebo | 114 | |
| Overall Study | Completed Ext. Phase | Everolimus LT Target of 3 to 7 ng/mL | 79 | |
| Overall Study | Completed Ext. Phase | Everolimus HT Target of 9 to 15 ng/mL | 92 | |
| Overall Study | Completed Ext. Phase | Placebo | 81 | |
| Overall Study | Continued in Post-Ext. Phase | Everolimus LT Target of 3 to 7 ng/mL | 78 | |
| Overall Study | Continued in Post-Ext. Phase | Everolimus HT Target of 9 to 15 ng/mL | 90 | |
| Overall Study | Continued in Post-Ext. Phase | Placebo | 81 | |
| Overall Study | Completed Post-Ext Phase | Everolimus LT Target of 3 to 7 ng/mL | 74 | |
| Overall Study | Completed Post-Ext Phase | Everolimus HT Target of 9 to 15 ng/mL | 85 | |
| Overall Study | Completed Post-Ext Phase | Placebo | 75 | |
| Overall Study | Did Not Continue in Ext Phase | Everolimus LT Target of 3 to 7 ng/mL | 0 | |
| Overall Study | Did Not Continue in Ext Phase | Everolimus HT Target of 9 to 15 ng/mL | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01713946/flow